nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.09.2010

Lipid replacement therapy: a nutraceutical approach for reducing cancer-associated fatigue and the adverse effects of cancer therapy while restoring mitochondrial function

verfasst von: Garth L. Nicolson

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Cancer-associated fatigue is one of the most common symptoms in all forms and stages of cancer, yet scant attention is usually given to patients who have symptomatic complaints of fatigue. Cancer-associated fatigue is also associated with cellular oxidative stress, and during cancer therapy, excess drug-induced oxidative stress can limit therapeutic effectiveness and cause a number of side effects, including fatigue, nausea, vomiting, and more serious adverse effects. Cancer-associated fatigue and the chronic adverse effects of cancer therapy can be reduced by lipid replacement therapy using membrane lipids along with antioxidants and enzymatic cofactors, such as coenzyme Q₁₀, given as food supplements. Administering these nutraceutical supplements can reduce oxidative membrane damage and restore mitochondrial and other cellular functions. Recent clinical trials using cancer and non-cancer patients with chronic fatigue have shown the benefits of lipid replacement therapy in reducing fatigue and restoring mitochondrial electron transport function.

Hofman, M., Ryan, J. L., Figueroa-Moseley, C. D., et al. (2007). Cancer-related fatigue: The scale of the problem. The Oncologist, 12, 4–10.PubMedCrossRef

Brown, L. F., & Kroenke, K. (2009). Cancer-related fatigue and its association with depression and anxiety: A systematic review. Psychosomatics, 50, 440–447.PubMedCrossRef

Prue, G., Rankin, J., Allen, J., et al. (2006). Cancer-related fatigue: A critical appraisal. European Journal of Cancer, 42, 846–863.PubMedCrossRef

Curt, G. A., Breitbart, W., Cella, D., et al. (2000). Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. The Oncologist, 5, 353–360.PubMedCrossRef

Respini, D., Jacobsen, P. B., Thors, C., et al. (2003). The prevalence and correlates of fatigue in older cancer patients. Critical Reviews in Oncology/Hematology, 47, 273–279.PubMedCrossRef

Sood, A., & Moynihan, T. J. (2005). Cancer-related fatigue: An update. Current Oncology Reports, 7, 277–282.PubMedCrossRef

Arnold, L. M. (2008). Understanding fatigue in major depressive disorder and other medical disorders. Psychosomatics, 49, 185–190.PubMedCrossRef

Bender, C. M., Engberg, S. J., Donovan, H. S., et al. (2008). Symptom clusters in adults with chronic health problems and cancer as a comorbidity. Oncology Nursing Forum, 35, E1–E11.PubMedCrossRef

Smets, E. M. A., Garssen, B., Cull, A., et al. (1996). Applications of the Multidimensional Fatigue Inventory (MFI-20) in cancer patients receiving radiotherapy. British Journal of Cancer, 73, 241–245.PubMed

10.

Stone, P., Hardy, J., Huddart, R., et al. (2000). Fatigue in patients with prostate cancer receiving hormone therapy. European Journal of Cancer, 36, 1134–1141.PubMedCrossRef

11.

Cella, D., Davis, K., Breitbart, W., et al. (2001). Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of Clinical Oncology, 19, 3385–3391.PubMed

12.

Ahlberg, K., Ekman, T., Gaston-Johansson, F., & Mock, V. (2003). Assessment and management of cancer-related fatigue in adults. The Lancet, 362(9384), 640–650.CrossRef

13.

Gutstein, H. B. (2001). The biological basis for fatigue. Cancer, 92, 1678–1683.PubMedCrossRef

14.

Manzullo, E. F., & Escalante, C. P. (2002). Research into fatigue. Hematology/Oncology Clinics of North America, 16, 619–628.PubMedCrossRef

15.

Given, B., Given, C., Azzouz, F., & Stommel, M. (2001). Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nursing Research, 50, 222–232.PubMedCrossRef

16.

Vogelzang, N., Breitbart, W., Cella, D., et al. (1997). Patient caregiver and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. Seminars in Hematology, 34(Suppl 2), 4–12.PubMed

17.

Liu, L., Marler, M. R., Parker, B. A., et al. (2005). The relationship between fatigue and light exposure during chemotherapy. Supportive Care in Cancer, 13, 1010–1017.PubMedCrossRef

18.

Marrow, G. R. (2007). Cancer-related fatigue: Causes, consequences and management. The Oncologist, 12(suppl 1), 1–3.CrossRef

19.

Morrison, J. D. (1980). Fatigue as a presenting complaint in family practice. The Journal of Family Practice, 10, 795–801.PubMed

20.

Kroenke, K., Wood, D. R., Mangelsdorff, A. D., et al. (1988). Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. JAMA, 260, 929–934.PubMedCrossRef

21.

McDonald, E., David, A. S., Pelosi, A. J., & Mann, A. H. (1993). Chronic fatigue in primary care attendees. Psychological Medicine, 23, 987–998.PubMedCrossRef

22.

Kehrer, J. P. (1993). Free radicals and mediators of tissue injury and disease. Critical Reviews in Toxicology, 23, 21–48.PubMedCrossRef

23.

Halliwell, B. (1996). Oxidative stress, nutrition and health. Free Radical Research, 25, 57–74.PubMedCrossRef

24.

Dreher, D., & Junod, A. F. (1996). Role of oxygen free radicals in cancer development. European Journal of Cancer, 32A, 30–38.PubMedCrossRef

25.

Abidi, S., & Ali, A. (1999). Role of oxygen free radicals in the pathogenesis and etiology of cancer. Cancer Letters, 142, 1–9.CrossRef

26.

Stadtman, E. (2002). Introduction to serial reviews on oxidatively modified proteins in aging and disease. Free Radical Biology & Medicine, 32, 789.CrossRef

27.

Marnett, L. J. (2000). Oxyradicals and DNA damage. Carcinogenesis, 21, 361–370.PubMedCrossRef

28.

Bartsch, H., & Nair, J. (2004). Oxidative stress and lipid peroxidation-driven DNA-lesions in inflammation driven carcinogenesis. Cancer Detection and Prevention, 28, 385–391.PubMedCrossRef

29.

Castro, L., & Freeman, B. A. (2001). Reactive oxygen species in human health and disease. Nutrition, 17, 295–307.CrossRef

30.

Johnson, T. M., Yu, Z. X., Ferrans, V. J., et al. (1996). Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proceedings of the National Academy of Science USA, 93, 11848–11852.CrossRef

31.

Ghaffari, S. (2008). Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxidation and Redox Signaling, 10, 1923–1940.CrossRef

32.

Maes, M. (2009). Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Current Opinions in Psychiatry, 22, 75–83.CrossRef

33.

Maes, M., & Twisk, F. N. (2009). Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: Disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS. Neuro Endocrinology Letters, 30, 677–693.PubMed

34.

Barber, D. A., & Harris, S. R. (1994). Oxygen free radicals and antioxidants: A review. American Pharmacology, 34, 26–35.

35.

Sun, Y. (1990). Free radicals, antioxidant enzymes and carcinogenesis. Free Radical Biology & Medicine, 8, 583–599.CrossRef

36.

Fridovich, I. (1995). Superoxide radical and superoxide dismutases. Annual Review of Biochemistry, 64, 97–112.PubMedCrossRef

37.

Seifried, H. E., McDonald, S. S., Anderson, D. E., et al. (2003). The antioxidant conundrum in cancer. Cancer Research, 61, 4295–4298.

38.

Jagetia, G. C., Rajanikant, G. K., Rao, S. K., et al. (2003). Alteration in the glutathione, glutathione peroxidase, superoxide dismutase and lipid peroxidation by ascorbic acid in the skin of mice exposed to fractionated gamma radiation. Clinica Chimica Acta, 332, 111–121.CrossRef

39.

Schwartz, J. L. (1996). The dual roles of nutrients as antioxidants and prooxidants: Their effects on tumor cell growth. The Journal of Nutrition, 126, 1221S–1227S.PubMed

40.

Aeschbach, R., Loliger, J., Scott, B. C., et al. (1994). Antioxidant actions of thymol, carvacrol, 6-gingerol, zingerone and hydroxytyrosol. Food Chemistry and Toxicology, 32, 31–36.CrossRef

41.

Tanaka, T. (1994). Cancer chemoprevention by natural products. Oncology Reports, 1, 1139–1155.

42.

Prasad, K. N., Cole, W. C., Kumar, B., et al. (2001). Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. Journal of the American College of Nutrition, 20, 450S–453S.PubMed

43.

Toyokuni, S., Okamoto, K., Yodio, J., et al. (1995). Persistent oxidative stress in cancer. FEBS Letters, 358, 1–3.PubMedCrossRef

44.

Ray, G., Batra, S., Shukla, N. K., et al. (2000). Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Research and Treatment, 59, 163–170.PubMedCrossRef

45.

Brown, N. S., & Bicknell, R. (2001). Hypoxia and oxidative stress in breast cancer. Oxidative stress: Its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Research, 3, 323–327.PubMedCrossRef

46.

Klaunig, J. E., & Kamendulis, L. M. (2004). The role of oxidative stress in carcinogenesis. Annual Review of Pharmacology and Toxicology, 44, 239–267.PubMedCrossRef

47.

Tas, F., Hansel, H., Belce, A., et al. (2005). Oxidative stress in breast cancer. Medical Oncology, 22, 11–15.PubMedCrossRef

48.

Kang, D. H. (2002). Oxidative stress, DNA damage and breast cancer. AACN Clinical Issues, 13, 540–549.PubMedCrossRef

49.

Sikka, S. C. (2003). Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention—a mechanistic approach. Current Medicinal Chemistry, 10, 2679–2692.PubMedCrossRef

50.

Aydin, A., Arsova-Sarafinovska, Z., Sayal, A., et al. (2006). Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostate hyperplasia. Clinical Biochemistry, 39, 176–179.PubMedCrossRef

51.

Otamiri, T., & Sjodahl, R. (1989). Increased lipid peroxidation in malignant tissues of patients with colorectal cancer. Cancer, 64, 422–425.PubMedCrossRef

52.

Oxdemirler, G., Pabucçoglu, H., Bulut, T., et al. (1989). Increased lipoperoxide levels and antioxidant system in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 124, 555–559.

53.

Asal, N. R., Risser, D. R., Kadamani, S., et al. (1990). Risk factors in renal cell carcinoma. I. Methodology, demographics, tobacco beverage use and obesity. Cancer Detection and Prevention, 11, 359–377.

54.

Gago-Dominguez, M., Castelao, J. E., Yuan, J. M., et al. (2002). Lipid peroxidation: A novel and unifying concept of the etiology of renal cell carcinoma. Cancer Causes & Control, 13, 287–293.CrossRef

55.

Manoharan, S., Kolanjiappan, K., Suresh, K., et al. (2005). Lipid peroxidation and antioxidants status in patients with oral squamous cell carcinoma. The Indian Journal of Medical Research, 122, 529–534.PubMed

56.

Seril, D. N., Liao, J., Yang, G. Y., et al. (2003). Oxidative stress and ulcerative colitis-associated carcinogenesis: Studies in humans and animal models. Carcinogenesis, 34, 353–362.CrossRef

57.

Batcioglu, K., Mehmet, N., Ozturk, I. C., et al. (2006). Lipid peroxidation and antioxidant status in stomach cancer. Cancer Investigation, 24, 18–21.PubMedCrossRef

58.

Jaruga, P., Zastawny, T. H., Skokowski, J., et al. (1992). Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Letters, 341, 59–64.CrossRef

59.

Conklin, K. A. (2004). Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. Integrated Cancer Therapies, 3, 294–300.CrossRef

60.

Nicolson, G. L., & Conklin, K. A. (2008). Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clinical & Experimental Metastasis, 25, 161–169.CrossRef

61.

Conklin, K. A. (2000). Dietary antioxidants during cancer chemotherapy: Impact on chemotherapeutic effectiveness and development of side effects. Nutrition and Cancer, 37, 1–18.PubMedCrossRef

62.

Betteridge, D. J. (2000). What is oxidative stress? Metabolism, 49(suppl 1), 3–8.PubMedCrossRef

63.

Hauptlorenz, S., Esterbauer, H., Moll, W., et al. (1985). Effects of the lipid peroxidation product 4-hydroxynonenal and related aldehydes on proliferation and viability of cultured Ehrlich ascites tumor cells. Biochemical Pharmacology, 34, 3803–3809.PubMedCrossRef

64.

Gonzalez, M. J. (1992). Lipid peroxidation and tumor growth: An inverse relationship. Medical Hypotheses, 38, 106–110.PubMedCrossRef

65.

Schackelford, R. E., Kaufmann, W. K., & Paules, R. S. (2000). Oxidative stress and cell cycle checkpoint function. Free Radical Biology & Medicine, 28, 1387–1404.CrossRef

66.

Balin, A. K., Goodman, D. B. P., Rasmussen, H., et al. (1978). Oxygen-sensitive stages of the cell cycle of human diploid cells. The Journal of Cell Biology, 78, 390–400.PubMedCrossRef

67.

Kurata, S. (2000). Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress. The Journal of Biological Chemistry, 275, 23413–23416.PubMedCrossRef

68.

Wei, Q., Frazier, M. L., & Levin, B. (2000). DNA repair: A double edge sword. Journal of the National Cancer Institute, 92, 440–441.PubMedCrossRef

69.

Fojo, T. (2001). Cancer, DNA repair mechanisms, and resistance to chemotherapy. Journal of the National Cancer Institute, 93, 1434–1436.PubMedCrossRef

70.

Zhen, W., Link, C. J., O'Connor, P. M., et al. (1992). Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Molecular and Cellular Biology, 12, 3689–3698.PubMed

71.

Lee, Y.-J., & Shacter, E. (1999). Oxidative stress inhibits apoptosis in human lymphoma cells. The Journal of Biological Chemistry, 274, 19792–19798.PubMedCrossRef

72.

Shacter, E., Williams, J. A., Hinson, R. M., et al. (2000). Oxidative stress interferes with cancer chemotherapy: Inhibition of lymphoma cell apoptosis and phagocytosis. Blood, 96, 307–313.PubMed

73.

Hampton, M. B., Fadeel, B., & Orrenius, S. (1998). Redox regulation of the caspases during apoptosis. Annals of the New York Academy of Sciences, 854, 328–335.PubMedCrossRef

74.

Chandra, J., Samali, A., & Orrenius, S. (2000). Triggering and modulation of apoptosis by oxidative stress. Free Radical Biology & Medicine, 29, 323–333.CrossRef

75.

Greenberger, J. S., Kagan, V. E., Pearce, L., et al. (2001). Modulation of redox signal transduction pathways in the treatment of cancer. Antioxidants Redox Signaling, 3, 347–359.PubMedCrossRef

76.

Feinendegen, L. E., Pollycove, M., & Neumann, R. D. (2007). Whole-body responses to low-level radiation exposure: New concepts in mammalian radiobiology. Experimental Hematology, 35, 37–46.PubMedCrossRef

77.

Epperly, M. W., Gretton, J. E., Sikora, C. A., et al. (2003). Mitochondrial localization of superoxide dismutase is required for decreasing radiation-induced cellular damage. Radiation Research, 160, 568–578.PubMedCrossRef

78.

Sabbarova, I., & Kanai, A. (2007). Targeted delivery of radioprotective agents to mitochondria. Molecular Interventions, 8, 295–302.

79.

Leach, J. K., Black, S. M., Schmidt-Ullrich, R. K., & Mikkelsen, R. B. (2002). Activation of constitutive nitric-oxide synthase activity is an early signaling event induced by ionizing radiation. The Journal of Biological Chemistry, 277, 15400–15406.PubMedCrossRef

80.

Conklin, K. A. (2005). Coenzyme Q₁₀ for prevention of anthracycline-induced cardiotoxicity. Integrated Cancer Therapies, 4, 110–130.CrossRef

81.

Lehninger, A. L. (1951). Phosphorylation coupled to oxidation of dihydrodiphosphopyridine nucleotide. The Journal of Biological Chemistry, 190, 345–359.PubMed

82.

Rasmussen, U. F., & Rasmussen, H. N. (1985). The NADH oxidase system (external) of muscle mitochondria and its role in the oxidation of cytoplasmic NADH. The Biochemical Journal, 229, 632–641.

83.

Nohl, H. (1987). Demonstration of the existence of an organo-specific NADH dehydrogenase in heart mitochondria. European Journal of Biochemistry, 169, 585–591.PubMedCrossRef

84.

Davies, K. J. A., & Doroshow, J. H. (1986). Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. Journal of Biological Chemistry, 261, 3060–3067.PubMed

85.

Doroshow, J. H., & Davies, K. J. A. (1986). Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. The Journal of Biological Chemistry, 261, 3068–3074.PubMed

86.

Gille, L., & Nohl, H. (1997). Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radical Biology & Medicine, 23, 775–782.CrossRef

87.

Eaton, S., Skinner, R., Hale, J. P., et al. (2000). Plasma coenzyme Q₁₀ in children and adolescents undergoing doxorubicin therapy. Clinica Chimica Acta, 302, 1–9.CrossRef

88.

Karlsson, J., Folkers, K., Astrom, H., et al. (1986). Effect of adriamycin on heart and skeletal muscle coenzyme Q₁₀ (CoQ₁₀) in man. In K. Folkers & Y. Yamamura (Eds.), Biomedical and clinical aspects of coenzyme Q (Vol. 5, pp. 241–245). Amsterdam: Elsevier.

89.

Papadopoulou, L. C., & Tsiftsoglou, A. S. (1996). Effects of hemin on apoptosis, suppression of cytochrome C oxidase gene expression, and bone-marrow toxicity induced by doxorubicin. Biochemical Pharmacology, 52, 713–722.PubMedCrossRef

90.

Palmeira, C. M., Serrano, J., Kuehl, D. W., et al. (1997). Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochimica et Biophysica Acta, 1321, 101–106.PubMedCrossRef

91.

Brizel, D. M. (2007). Pharmacologic approaches to radiation protection. Journal of Clinical Oncology, 25, 4084–4089.PubMedCrossRef

92.

Domae, N., Sawada, H., Matsuyama, E., et al. (1981). Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q₁₀. Cancer Treatment Reports, 65, 79–91.PubMed

93.

Usui, T., Ishikura, H., Izumi, Y., et al. (1982). Possible prevention from the progression of cardiotoxicity in adriamycin-treated rabbits by coenzyme Q₁₀. Toxicology Letters, 12, 75–82.PubMedCrossRef

94.

Judy, W. V., Hall, J. H., Dugan, W., et al. (1984). Coenzyme Q₁₀ reduction of adriamycin cardiotoxicity. In K. Folkers & Y. Yamamura (Eds.), Biomedical and clinical aspects of coenzyme Q (Vol. 4, pp. 231–241). Amsterdam: North-Holland Biomedical.

95.

Cortes, E. P., Gupta, M., Chou, C., et al. (1978). Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q₁₀. Cancer Treatment Reports, 62, 887–891.PubMed

96.

Buckingham, R., Fitt, J., & Sitzia, J. (1997). Patients’ experience of chemotherapy: Side-effects of carboplatin in the treatment of carcinoma of the ovary. European Journal of Cancer Care, 6, 59–71.PubMedCrossRef

97.

Iarussi, D., Auricchio, U., Agretto, A., et al. (1994). Protective effect of coenzyme Q₁₀ on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Molecular Aspects of Medicine, 15, S207–S212.PubMedCrossRef

98.

Loke, Y. K., Price, D., Derry, S., et al. (2006). Case reports of suspected adverse drug reactions—systematic literature survey of follow-up. British Medical Journal, 232, 335–339.CrossRef

99.

Von Roenn, J. H., & Paice, J. A. (2005). Control of common, non-pain cancer symptoms. Seminars in Oncology, 32, 200–210.CrossRef

100.

Borneman, T., Piper, B. F., Sun, V. C., et al. (2007). Implementing the fatigue guidelines at one NCCN member institution: Process and outcomes. Journal of the National Comprehensive Cancer Network, 5, 1092–1101.PubMed

101.

Escalante, C. P., Kallen, M. A., Valdres, R. U., et al. (2010). Outcomes of a cancer-related fatigue clinic in a comprehensive cancer center. Journal of Pain and Symptom Management, 39, 691–701.PubMedCrossRef

102.

Ryan, J. L., Carroll, J. K., Ryan, E. P., et al. (2007). Mechanisms of cancer-related fatigue. The Oncologist, 12(Suppl. 1), 22–34.PubMedCrossRef

103.

Mustian, K. M., Morrow, G. R., Carroll, J. K., et al. (2007). Integrative nonpharmacological behavioral interventions for the management of cancer-related fatigue. The Oncologist, 12(Suppl. 1), 52–67.PubMedCrossRef

104.

Watson, T., & Mock, V. (2004). Exercise as an intervention for cancer-related fatigue. Physical Therapy, 84, 736–743.PubMed

105.

Zee, P. C., & Acoli-Isreal, S. (2009). Does effective management of sleep disorders reduce cancer-related fatigue? Drugs, 69(Suppl. 2), 29–41.PubMedCrossRef

106.

Milton, O., Richardson, A., Sharpe, M., et al. (2008). A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. Journal of the National Cancer Institute, 100, 1–12.

107.

Levy, M. (2008). Cancer fatigue: A review for psychiatrists. General Hospital Psychiatry, 30, 233–244.PubMedCrossRef

108.

Nicolson, G. L. (2003). Lipid replacement as an adjunct to therapy for chronic fatigue, anti-aging and restoration of mitochondrial function. Journal of the American Nutraceutical Association, 6(3), 22–28.

109.

Agadjanyan, M., Vasilevko, V., Ghochikyan, A., et al. (2003). Nutritional supplement (NTFactor) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. Journal of Chronic Fatigue Syndrome, 11(3), 23–26.CrossRef

110.

Nicolson, G. L. (2005). Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function. Pathology Oncology Research, 11, 139–144.PubMedCrossRef

111.

Wei, Y. H., & Lee, H. C. (2002). Oxidative stress, mitochondrial DNA mutation and impairment of antioxidant enzymes in aging. Experimental Biology and Medicine, 227, 671–682.PubMed

112.

Huang, H., & Manton, K. G. (2004). The role of oxidative damage in mitochondria during aging: A review. Frontiers in Bioscience, 9, 1100–1117.PubMedCrossRef

113.

Logan, A. C., & Wong, C. (2001). Chronic fatigue syndrome: Oxidative stress and dietary modifications. Alternative Medicine Review, 6, 450–459.PubMed

114.

Manuel, y, Keenoy, B., Moorkens, G., Vertommen, J., & De Leeuw, I. (2001). Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Science, 68, 2037–2049.CrossRef

115.

Richards, R. S., Roberts, T. K., McGregor, N. R., et al. (2000). Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Reports, 5, 35–41.

116.

Felle, S., Mecocci, P., Fano, G., et al. (2000). Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radical Biology & Medicine, 29, 1252–1259.CrossRef

117.

Dianzani, M. U. (1993). Lipid peroxidation and cancer. Critical Reviews in Oncology/Hematology, 15, 125–147.PubMedCrossRef

118.

Pall, M. L. (2000). Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Medical Hypotheses, 54, 115–125.PubMedCrossRef

119.

Nicolson, G. L., Poste, G., & Ji, T. (1977). Dynamic aspects of cell membrane organization. Cell Surface Reviews, 3, 1–73.

120.

Subczynski, W. K., & Wisniewska, A. (2000). Physical properties of lipid bilayer membranes: Relevance to membrane biological functions. Acta Biochimica Polonica, 47, 613–625.PubMed

121.

Radi, R., Rodriguez, M., Castro, L., et al. (1994). Inhibition of mitochondrial electronic transport by peroxynitrite. Archives of Biochemistry and Biophysics, 308, 89–95.PubMedCrossRef

122.

Kanno, T., Sato, E. E., Muranaka, S., et al. (2004). Oxidative stress underlies the mechanism for Ca(2+)-induced permeability transition of mitochondria. Free Radical Research, 38, 27–35.PubMedCrossRef

123.

Nicolson, G. L., & Ellithrope, R. (2006). Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. Journal of Chronic Fatigue Syndrome, 13(1), 57–68.CrossRef

124.

Ellithorpe, R. R., Settineri, R., & Nicolson, G. L. (2003). Reduction of fatigue by use of a dietary supplement containing glycophospholipids. Journal of the American Nutraceutical Association, 6(1), 23–28.

125.

Mansbach, C. M., & Dowell, R. (2000). Effect of increasing lipid loads on the ability of the endoplasmic reticulum to transport lipid to the Golgi. Journal of Lipid Research, 41, 605–612.PubMed

126.

Seidman, M., Khan, M. J., Tang, W. X., et al. (2002). Influence of lecithin on mitochondrial DNA and age-related hearing loss. Otolaryngology - Head and Neck Surgery, 127, 138–144.PubMedCrossRef

127.

Piper, B. F., Linsey, A. M., & Dodd, M. J. (1987). Fatigue mechanism in cancer. Oncology Nursing Forum, 14, 17–23.PubMed

128.

Nicolson, G. L., Ellithorpe, R. R., Ayson-Mitchell, C., et al. (2010). Lipid replacement therapy with a glycophospholipid–antioxidant–vitamin formulation significantly reduces fatigue within one week. Journal of the American Nutraceutical Association, 13(1), 11–15.

129.

Colodny, L., Lynch, K., Farber, C., et al. (2000). Results of a study to evaluate the use of Propax to reduce adverse effects of chemotherapy. Journal of the American Nutraceutical Association, 2(1), 17–25.

Titel: Lipid replacement therapy: a nutraceutical approach for reducing cancer-associated fatigue and the adverse effects of cancer therapy while restoring mitochondrial function
verfasst von: Garth L. Nicolson
Publikationsdatum: 01.09.2010
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2010
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9245-0

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Lipid replacement therapy: a nutraceutical approach for reducing cancer-associated fatigue and the adverse effects of cancer therapy while restoring mitochondrial function

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

The role of nutraceutical proteins and peptides in apoptosis, angiogenesis, and metastasis of cancer cells

Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis

Micronutrient synergy—a new tool in effective control of metastasis and other key mechanisms of cancer

Inhibition of cancer cell invasion and metastasis by genistein

Cancer and metastasis: prevention and treatment by green tea

Tomato-based food products for prostate cancer prevention: what have we learned?

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie